Vitamin B12 Injections

LCD Information Document Information Source LCD ID N/A LCD ID L33967 Original ICD-9 LCD ID Not Applicable LCD Title Vitamin B12 Injections Proposed LCD in Comment Period N/A Source Proposed LCD N/A Original Effective Date For services performed on or after 10/01/2015 Revision Effective Date For services performed on or after 01/01/2021 Revision Ending Date N/A Retirement Date N/A Notice Period Start Date N/A Notice Period End Date N/A CPT codes, descriptions, and other data only are copyright 2025 American Medical Association. All Rights Reserved. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. CPT is a registered trademark of the American Medical Association. Current Dental Terminology © 2025 American Dental Association. All rights reserved. Copyright © 2026, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution, or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at ub04@aha.org or 312‐422‐3366. Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates. Issue Issue Description Issue - Explanation of Change Between Proposed LCD and Final LCD CMS National Coverage Policy This LCD supplements but does not replace, modify or supersede existing Medicare applicable National Coverage Determinations (NCDs) or payment policy rules and regulations for Vitamin B12 Injections. Federal statute and subsequent Medicare regulations regarding provision and payment for medical services are lengthy. They are not repeated in this LCD. Neither Medicare payment policy rules nor this LCD replace, modify or supersede applicable state statutes regarding medical practice or other health practice professions acts, definitions and/or scopes of practice. All providers who report services for Medicare payment must fully understand and follow all existing laws, regulations and rules for Medicare payment for Vitamin B12 Injections and must properly submit only valid claims for them. Please review and understand them and apply the medical necessity provisions in the policy within the context of the manual rules. Relevant CMS manual instructions and policies may be found in the following Internet-Only Manuals (IOMs) published on the CMS Web site. Internet Only Manual (IOM) Citations: CMS IOM Publication 100-02, Medicare Benefit Policy Manual, Chapter 1, Section 30 Drugs and Biologicals Chapter 6, 20.5.3 Coverage of Outpatient Therapeutic Services Incident to a Physician’s Service Furnished on or After January 1, 2020 – Changes to Supervision Requirements Chapter 15, Section 50 Drugs and Biologicals and Section 60 Services and Supplies CMS IOM Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2, Section 150.6 Vitamin B12 Injections to Strengthen Tendons, Ligaments, etc., of the Foot CMS IOM Publication 100-04, Medicare Claims Processing Manual, Chapter 17 Drugs and Biologicals Chapter 23, Section 20.9 National Correct Coding Initiative (CCI) CMS IOM Publication 100-08, Medicare Program Integrity Manual, Chapter 13, Section 13.5.4 Reasonable and Necessary Provision in an LCD Social Security Act (Title XVIII) Standard References: Title XVIII of the Social Security Act, Section 1862(a)(1)(A) states that no Medicare payment shall be made for items or services which are not reasonable and necessary for the diagnosis or treatment of illness or injury. Title XVIII of the Social Security Act, Section 1862(a)(7). This section excludes routine physical examinations. Coverage Indications, Limitations, and/or Medical Necessity Compliance with the provisions in this LCD may be monitored and addressed through post payment data analysis and subsequent medical review audits. History/Background and/or General Information Vitamin B12 is essential for the formation of red blood cells and is used in the treatment of diseases in which there is defective red cell formation. Covered Indications Vitamin B12 injection will be considered medically reasonable and necessary under the following circumstances: Vitamin B12 administration by injection is a covered benefit accepted as medically necessary when the beneficiary has a history of a low serum B12 or conditions causing or caused by a low serum B12. In addition, vitamin B12 will be considered medically reasonable and necessary when administered as an adjunct to pemetrexed or pralatrexate treatment as follows: For pemetrexed patients, patients must receive one intramuscular injection of vitamin B12 during the week preceding the first dose of pemetrexed and every three cycles thereafter For pralatrexate patients, supplement patients with vitamin B12 1 mg intramuscularly no more than 10 weeks prior to the first dose of pralatrexate, and every 8-10 weeks thereafter Subsequent vitamin B12 injections may be given the same day as either pemetrexed or pralatrexate. Limitations Please refer to CMS IOM Publication 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 2, Section 150.6 Vitamin B12 Injections to Strengthen Tendons, Ligaments, etc., of the Foot regarding non coverage. Notice: Services performed for any given diagnosis must meet all of the indications and limitations stated in this LCD, the general requirements for medical necessity as stated in CMS payment policy manuals, any and all existing CMS national coverage determinations, and all Medicare payment rules. Summary of Evidence N/A Analysis of Evidence (Rationale for Determination) N/A

Compliance with the provisions in this LCD may be monitored and addressed through post payment data analysis and subsequent medical review audits. History/Background and/or General Information Vitamin B 12 is essential for the formation of red blood cells and is used in the treatment of diseases in which there is defective red cell formation. Covered Indications Vitamin B 12 injection will be considered medically reasonable and necessary under the following circumstances: Vitamin B 12 administration by injection is a covered benefit accepted as medically necessary when the beneficiary has a history of a low serum B 12 or conditions causing or caused by a low serum B 12 . In addition, vitamin B 12 will be considered medically reasonable and necessary when administered as an adjunct to pemetrexed or pralatrexate treatment as follows: For pemetrexed patients, patients must receive one intramuscular injection of vitamin B 12 during the week preceding the first dose of pemetrexed and every three cycles thereafter For pralatrexate patients, supplement patients with vitamin B 12 1 mg intramuscularly no more than 10 weeks prior to the first dose of pralatrexate, and every 8-10 weeks thereafter Subsequent vitamin B 12 injections may be given the same day as either pemetrexed or pralatrexate. Limitations Please refer to CMS IOM Publication 100-03, Medicare National Coverage Determinations (NCD) Manual , Chapter 1, Part 2, Section 150.6 Vitamin B 12 Injections to Strengthen Tendons, Ligaments, etc., of the Foot regarding non coverage. Notice: Services performed for any given diagnosis must meet all of the indications and limitations stated in this LCD, the general requirements for medical necessity as stated in CMS payment policy manuals, any and all existing CMS national coverage determinations, and all Medicare payment rules.